Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Harry Glorikian Video
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(339)
•••
Comment by kodiakupon Oct 11, 2020 8:38pm
318 Views
Post# 31703256

RE:RE:Harry Glorikian Video

RE:RE:Harry Glorikian Video

 

Accueil Zonebourse  >  Informations  >  Accueil  >  Biographies des Barons

Les Barons de la Bourse

  
Toute l'info Socits Marchs Economie & Forex Mat. Premires Taux Barons de la bourse Pro. de la finance Agenda Secteurs  
Accueil Toute l'actualit Les news les plus lues Biographies des Barons
 
Portrait de Harry A. Glorikian

Harry A. Glorikian

Age : 53
Patrimoine public : 34 665 USD
Principales socits :  StageZero Life Sciences Ltd.
Synthse  
Harry A. Glorikian is an entrepreneur who founded Scientia Advisors LLC, X-Cell Laboratories and Drawbridge Health, Inc. Currently, he occupies the position of Chief Executive Officer & Director at Transparency Life Sciences, Inc. Mr. Glorikian is also on the board of StageZero Life Sciences Ltd. and General Partner of New Ventures Funds.

In his past career Mr. Glorikian was Managing Partner at Scientia Advisors LLC, Senior Manager at PE Applied Biosystems and Head-Global Sales at BioLegend CNS, Inc.

He received an MBA and an undergraduate degree from Boston University and an undergraduate degree from San Francisco State University.

 
Postes et responsabilits de Harry A. Glorikian  
Nom Titre Depuis
 StageZero Life Sciences Ltd.
(Recherche biotechnologique et mdicale)		 Independent Director 2008
Transparency Life Sciences, Inc. Chief Executive Officer & Director -
New Ventures Funds General Partner -

 
Participations de Harry A. Glorikian  
Nom Actions % Valorisation
 StageZero Life Sciences Ltd. (SZLS)
(Recherche biotechnologique et mdicale)		 568 275 0,15% 34 665 USD

 
Harry A. Glorikian: Rseau personnel  

  
Harry A. Glorikian : Connexions  




































































































 
   
 
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities